
NOT AN
ACTUAL
PATIENT.
GILENYA HELPS ADULTS
FIGHT RRMS IN 3 KEY WAYS
Over the course of 16+ years of clinical trial experience, once-a-day* GILENYA:
CUT RELAPSES
SLOWED DISABILITY
PROGRESSION
REDUCED LESIONS
CUT RELAPSES
SLOWED DISABILITY
PROGRESSION
REDUCED LESIONS

GILENYA HELPS ADULTS FIGHT RRMS IN 3 KEY WAYS
Over the course of 16+ years of
clinical trial experience, once-a-day*
GILENYA:
CUT RELAPSES
SLOWED DISABILITY
PROGRESSION
REDUCED LESIONS
CUT RELAPSES
SLOWED DISABILITY
PROGRESSION
REDUCED LESIONS

Reduced relapses in trials vs placebo, Avonex®, and Copaxone®
GILENYA offers strong results when
it comes to cutting relapses, and we
proved it in a study against placebo,
and in head-to-head studies against
Avonex (interferon beta-1a) and
Copaxone (glatiramer acetate
injection) 20 mg.

In a 2-year study against placebo, GILENYA reduced the number of relapses by 54%.
In a 2-year study against placebo, GILENYA reduced the number of relapses by 54%.

In a 1-year study against Avonex (interferon beta-1a), GILENYA reduced the number of relapses by 52%.
In a 1-year study against Avonex (interferon beta-1a), GILENYA reduced the number of relapses by 52%.

In a 1-year study against Copaxone (glatiramer acetate injection) 20 mg once daily, GILENYA reduced the number of relapses by 41%.
In a 1-year study against Copaxone (glatiramer acetate injection) 20 mg once daily, GILENYA reduced the number of relapses by 41%.



Kept more people relapse free

In a 2-year study, 70% of adults taking GILENYA had no relapses vs 46% of adults taking placebo.


In a 1-year study, 83% of adults taking GILENYA had no relapses vs 70% of adults taking Avonex.


Slowed down disability progression

IN A 1-YEAR STUDY AGAINST
AVONEX, THERE WAS NO SIGNIFICANT DIFFERENCE IN DISABILITY PROGRESSION.
Disability progression was measured every 3 months using the Expanded Disability Status Scale (EDSS).


Reduced the number of lesions seen on MRI scans
GILENYA was shown to reduce 2 key types of lesions seen on MRI.
Gd+ T1 lesions (areas that are inflamed right now)
T2 lesions (scarring from old and new inflammation
that shows how MS affects the brain over time)
In a 2-year study vs placebo:

T1: 0.2 FOR GILENYA VS 1.1 FOR PLACEBO
T1: 0.2 FOR GILENYA VS 1.1 FOR PLACEBO

T2: 2.5 FOR GILENYA VS 9.8 FOR PLACEBO
T2: 2.5 FOR GILENYA VS 9.8 FOR PLACEBO
In a 1-year study vs Avonex:

T1: 0.2 FOR GILENYA VS 0.5 FOR AVONEX
T1: 0.2 FOR GILENYA VS 0.5 FOR AVONEX

T2: 1.6 FOR GILENYA VS 2.6 FOR AVONEX
T2: 1.6 FOR GILENYA VS 2.6 FOR AVONEX
MORE ADULTS WHO STARTED ON GILENYA,
STAYED ON GILENYA
A study showed that 352 adults out of 433 (81%) who started GILENYA were still taking it 1 year later. By contrast, only 125 people out of 428 (29%) who started on an interferon beta injection or glatiramer acetate injectable treatment were still sticking with it after 1 year.
AFTER 1 YEAR:

At the start of the study, everyone was taking either GILENYA or one of the common injectable treatments: interferon beta or glatiramer acetate.



SUPPORT YOU CAN RELY ON
The GILENYA Go Program® has your back. From the day you're prescribed GILENYA, we start working for you—from answering your questions to finding ways for you to save. Just another reason to ask for GILENYA.
Need help?
The Go Program is a support program designed for you. If you are already taking GILENYA, you can receive dedicated one-on-one ongoing support, information on your medication, and educational resources. Sign up today!
Call us at 1-800-GILENYA (1-800-445-3692), 8:00 AM–9:00 PM ET, Mon–Fri.†
Call us at 1-800-GILENYA (1-800-445-3692), 8:00 AM–9:00 PM ET, Mon–Fri.†
If you're calling for your child ages 10 to 17, you can call our dedicated parent line at 1-800-598-1410 during the hours above.
If you're calling for your child ages 10 to 17, you can call our dedicated parent line at 1-800-598-1410 during the hours above.
Learn more about getting started


READY TO ASK
FOR GILENYA?
Your treatment preferences matter! Tell your health care professional you want to fight back with GILENYA. Starting the conversation is simple with this Self-Assessment.



READY TO ASK
FOR GILENYA?
Your treatment preferences matter! Tell your health care professional you want to fight back with GILENYA. Starting the conversation is simple with this Self-Assessment.




—GILENYA COMMUNITY MEMBER
This community member was paid for their time.
Individual results may vary.


—GILENYA COMMUNITY MEMBER
This community member was paid for their time.
Individual results may vary.
Gd+=gadolinium enhancing; MRI=magnetic resonance imaging; RRMS=relapsing-remitting multiple sclerosis.
Avonex and Copaxone are registered trademarks of their respective owners.
GO PROGRAM is a registered trademark of Novartis AG.
*GILENYA can result in a slow heart rate when first taken. You will be observed by a health care professional for at least 6 hours after you take your first dose. You may need to repeat this monitoring if you miss a dose or are a child who is moving to 0.5 mg from the 0.25 mg dose.
†Excludes public holidays.